ALIMP — Implanet SA Share News
0.000.00%
Last trade - 00:00- €26.60m
- €29.52m
- €12.47m
Brief: Implanet launches Jazz Evo For Degenerative Spine Disease In Adults
Brief: Implanet Q1 Revenue Down At 1.9 Million Euros
Brief: Implanet FY Net Loss Narrows At 6.6 Million Euros
Brief: Implanet And L&K Biomed Finalize Partnership With Cross-Distribution Agreements
Brief: Implanet 2017 Revenue Of EUR 7.8 Million
Brief: Implanet Announces Strategic Partnership With L&K BIOMED
Brief: Implanet Transfers Liquidity Contract With Oddo Corporate Finance To Tradition Securities And Futures
Brief: Implanet raises 1.75 million with u.s. Investors
Brief: Implanet announces CE mark clearance for JAZZ Passer
Brief: Implanet Q3 sales rise to 1.8 million euros
Brief: Implanet announces grant of two new patents in the U.S.
Brief: Implanet H1 operating loss narrows to 3.5 million euros
Brief: Implanet receives FDA clearance to market new Jazz Passer
Brief: Implanet announces positive clinical analysis results of JAZZ implants
Brief: Implanet Q2 revenue stable at EUR 2.1 mln
Brief: Implanet announces shares admission to trading on Euronext Growth Market
Brief: Implanet obtains US/EU marketing clearance for new JAZZ braid
Brief: Implanet's new JAZZ Standalone implant receives European marketing clearance
Brief: Implanet Q1 revenue stable at 2.0 million euros